|
|
| | 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Basic information |
| Product Name: | 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- | | Synonyms: | 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-;Finafloxacin;BAY35-3377,finafloxacin hydrochloride;8-cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;Finafloxacin (BAY35-3377);100827;(-)-(4aS,7aS)-8-Cyano-1-cyclopropyl-6-fluoro-4-oxo-7-(perhydropyrrolo[3,4-b]-1,4-oxazin-6-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride | | CAS: | 209342-40-5 | | MF: | C20H19FN4O4 | | MW: | 398.39 | | EINECS: | | | Product Categories: | | | Mol File: | 209342-40-5.mol | ![3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Structure](CAS/GIF/209342-40-5.gif) |
| | 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Chemical Properties |
| Boiling point | 686.2±55.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO : 6.4 mg/mL (16.06 mM) | | pka | 6.38±0.50(Predicted) | | form | powder | | color | white to beige |
| | 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Usage And Synthesis |
| Description | Finafloxacin, an antimicrobial agent of the 8-cyano subclass of
fluoroquinolones, was approved by the US FDA in December
2014 for treatment of acute otitis externa, commonly known as
swimmer’s ear, caused by susceptible strains of Pseudomonas
aeruginosa and Staphylococcus aureus. Finafloxacin was
developed by MerLion Pharmaceuticals in partnership with Bayer
Health Care Pharmaceuticals, and the drug was licensed by Mer-
Lion to Alcon (a division of Novartis) for development and commercialization
for ear infections in North America. In
contrast to other marketed fluoroquinolones, which display
reduced activity in slightly acidic environments, finafloxacin exhibits
increased antibacterial activity at pH 5–6, with minimum inhibitory
concentration values that are 4- to 8-fold lower than at
neutral pH. It is highly selective for bacterial type II topoisomerases,
which are involved in bacterial DNA replication, transcription,
repair, and recombination, and has broad spectrum
antibacterial activity against Gram-positive and Gram-negative
strains, including ciprofloxacin-resistant strains. | | Uses | Used for the preparation of naphthyridonecarboxylic acid derivatives as drugs for therapy of Helicobacter pylori infections and associated gastroduodenal illnesses. | | Definition | ChEBI: A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, 7 and 8 by cyclopropyl, fluoro, hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl and cyano groups respectively; an antibiotic used for treatment of
acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. | | Biochem/physiol Actions | Finafloxacin is a fluoroquinolone antibiotic approved by the FDA in 2014 for treating swimmer′s ear. Its mechanism of action involves the inhibition of bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV | | Synthesis | Synthesis of finafloxacin has been reported on kilogram scale
starting from 5-fluoro-1,3-xylene (104). Catalytic
chlorination through the use of FeCl3 in 1,2-dichloroethane (DCE)
was followed by a photochemical chlorination at elevated temperatures
to generate the polychlorinated intermediate 105 in 45%
yield over two steps. The polychlorinated system 105 was then
hydrolyzed with concentrated sulfuric acid to arrive at 3-formylbenzoic
acid 106. Conversion of the formyl group to nitrile and
the acid to the acid chloride was achieved in two steps, via condensation
of the aldehyde with hydroxylamine hydrochloride in the
presence of 45% NaOH and subsequent treatment with refluxing
thionyl chloride to afford 107 in 62% yield for the two steps. Acid
chloride 107 was converted to quinolone 109 through the following
4-step sequence, which was conducted without isolation of
intermediates?a107 was first coupled with ethyl 3-dimethylamino-
acrylate 108 in DCM in the presence of DIPEA followed
by condensation with cyclopropylamine in the presence of acetic
acid. This was followed by treatment with potassium carbonate
in warm NMP and, upon acidification, ethyl ester 109 was furnished
in a remarkable 90% yield over the sequence. Acidic hydrolysis
of ester 109 generated acid 110, which underwent coupling
with pyrrolo-oxazine 111 in the presence of triethylamine (TEA) and warm acetonitrile
to provide finafloxacin (XIV) in 90% yield from 109.
The synthesis of pyrrolo-oxazine fragment 111 commenced
with (Z)-butene-1,4-diol (112).120 Mesylation of this
diol followed by reaction with tosylamide under phase transfer
conditions afforded dihydropyrrole 113. Epoxidation of the olefin
using 3-chloroperoxybenzoic acid (m-CPBA) to give 114, followed
by subjection to ethanolamine affected an epoxide ring opening
to give rise to the trans aminoalcohol rac-115. Tosylation and
cyclization upon treatment with methanolic sodium hydroxide
gave the bis-toluenesulfonamide 116, which was resolved at this
point to >99% ee by chiral chromatography to arrive at the desired
(S,S)-enantiomer. Removal of the tosyl protecting groups within
116 using hydrobromic acid in glacial acetic acid preceded treatment
with KOH to finally furnish pyrrolo-oxazine 111.
|
| | 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Preparation Products And Raw materials |
|